SUBSCRIBE
SUBSCRIBE
News   Drug Development

Repros Therapeutics Inc. Release: FDA Provides Recommendations for Phase 2 Protocol for Low Dose Oral Proellex(R) in the Treatment of Endometriosis

August 28, 2012 | 
1 min read

THE WOODLANDS, Texas, Aug. 27, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the FDA has provided guidance for a Phase 2 study of low dose oral Proellex® in the treatment of endometriosis. The following are the key elements of the guidance:

Clinical research Phase II
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Pictured: AstraZeneca's manufacturing facility in Sweden
Adcomms
AstraZeneca Fends Off Adcomm’s Safety Concerns on Andexxa, Axes Mid-Stage Opioid Use Disorder Drug
November 22, 2024
 · 
3 min read
 · 
Tristan Manalac
A handshake of businessmen. Modern design with a positive context. Concept of help, support, and agreement between businessmen. Modern art collage, trendy magazine style.
Mergers & Acquisitions
Novartis CEO Promises More Deals of Up to $5B, With an Eye for Early Science
November 21, 2024
 · 
2 min read
 · 
Annalee Armstrong
broken human head conceptual digital illustration
Huntington’s disease
Sage Scraps Huntington’s Hopeful After Disappointing Phase II Data
November 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Human liver protection. Wireframe low poly style. Concept for medical, pharmacology, treatment of the hepatitis. Abstract modern 3d vector illustration on dark blue background.
MASH
Novo, Viking Heat Up MASH Space with Promising Data at AASLD24
November 20, 2024
 · 
3 min read
 · 
Tristan Manalac